Niagen Bioscience’s Exciting Corporate Name Change and Nasdaq Listing
In an exciting turn of events, Niagen Bioscience, Inc., previously known as ChromaDex Corp., has recently announced that it has officially changed its corporate name to Niagen Bioscience, Inc. This name change signifies a new era for the company, which has a strong focus on the science of healthy aging and the global authority on NAD+ (nicotinamide adenine dinucleotide).
Impact on Niagen Bioscience
This name change is a strategic move to better reflect the company’s core business and its mission to advance the science and commercialization of NAD+ and its role in healthy aging. The new name also aligns with the company’s growing presence in the bioscience industry and its commitment to innovation and scientific advancement.
Impact on Consumers
For consumers, this name change may not have an immediate impact, but it could lead to increased awareness and interest in Niagen Bioscience’s products and research. The company’s focus on NAD+ and healthy aging is a growing area of interest, and the new name is more reflective of the company’s mission and expertise.
Impact on the World
On a larger scale, Niagen Bioscience’s name change and Nasdaq listing could have a significant impact on the world of bioscience and healthy aging. As the global population continues to age, the demand for innovative solutions to promote healthy aging and improve overall health is increasing. Niagen Bioscience’s focus on NAD+ and its role in healthy aging could lead to new discoveries and advancements in this field.
Nasdaq Listing
In addition to the name change, Niagen Bioscience’s common stock will begin trading under the new Nasdaq symbol “NAGE” at stock market open on March 19, 2025. This listing is a significant milestone for the company and provides increased visibility and accessibility to potential investors.
Conclusion
Niagen Bioscience’s name change and Nasdaq listing are exciting developments for the company and the bioscience industry as a whole. The new name better reflects the company’s focus on NAD+ and healthy aging, and the Nasdaq listing provides increased visibility and accessibility to potential investors. As Niagen Bioscience continues to advance the science and commercialization of NAD+, we can look forward to new discoveries and innovations in the field of healthy aging.
- Niagen Bioscience changes corporate name to better reflect focus on NAD+ and healthy aging
- Company’s common stock begins trading under new Nasdaq symbol “NAGE” on March 19, 2025
- Impact on consumers, Niagen Bioscience, and the world
